Shifting Tides Offer New Hope For Obesity
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Obesity is a chronic disease affecting millions of people — in 2020, the Centers for Disease Control and Prevention (CDC) reported that the overall prevalence of obesity in the United States during the period from 2017 through 2018 was 42.5%.1 The development of type 2 diabetes is a complication of obesity that leads to greater mortality primarily due to a higher incidence of cancer, cardiovascular disease, and kidney disease2 The medical effects of obesity, especially type 2 diabetes, have a greater impact on some groups — particularly Black, Hispanic, and Native Americans — than on others, adding to notable health . . .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
The ominous triad of adipose tissue dysfunction: inflammation, fibrosis, and impaired angiogenesis.
Crewe, C., An, Y. A., & Scherer, P. E. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88883 · Cited by 732
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299
Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
Maselli, D. B., & Camilleri, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_496 · Cited by 248
Research works printed but not linked: 4
- 10.21037/atm.2017.03.107 · DOI · Paper page
- 10.1111/obr.12916 · DOI · Paper page
- 10.1007/s00592-021-01722-w · DOI
- 10.4239/wjd.v6.i15.1285 · DOI · Paper page
Cited by
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174
Tirzepatide Once Weekly for the Treatment of Obesity
(2022) · New England Journal of Medicine · doi:10.1056/nejmc2211120 · Cited by 71
le Roux, C. W., Hankosky, E. R., Wang, D., Malik, R., Yu, M., Hickey, A., Kan, H., Bunck, M. C., Stefanski, A., Garcia‐Perez, L., et al. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15148 · Cited by 36
“4 mg and tirzepatide represent new classes of antiobesity medications with powerful efficacy, with weight loss of 15% or greater.(13) This is the first comparison of tirzepatide 10 and 15 mg with semaglutide 2.”
BackgroundRetatrutide: A Triple Incretin Receptor Agonist for Obesity Management
Ray, A. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2276754 · Cited by 11
Metadata
- Authors
- Rosen, C. J., & Ingelfinger, J. R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 271-273
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281872642
- Cited by
- 17
- References
- 5
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Shifting Tides Offer New Hope For Obesity. https://app.cochat.ai/papers/10.1056/nejme2206939
- The paper
- Rosen, C. J., & Ingelfinger, J. R. (2022). Shifting Tides Offer New Hope For Obesity. New England Journal of Medicine. https://doi.org/10.1056/nejme2206939
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.